This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (DOSE-HEP)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2010 by South West Sydney Local Health District.
Recruitment status was:  Recruiting
Information provided by:
South West Sydney Local Health District Identifier:
First received: March 1, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted
Sorafenib improves overall survival and progression free survival in advanced hepatocellular carcinoma. Wide interindividual pharmacokinetic variability was observed. Data from early phase trials in solid tumours showed trough sorafenib levels were associated with incidence of skin rash and hypertension. Rash, hypertension and higher trough levels were moderately predictive of progression free survival.The trough level of sorafenib may be predictive of survival and response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Hepatocellular Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Phase 2 Study of Measurement of Trough Levels of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Resource links provided by NLM:

Further study details as provided by South West Sydney Local Health District:

Primary Outcome Measures:
  • To demonstrate the correlation of trough sorafenib level with overall survival in advanced hepatocellular carcinoma [ Time Frame: 4 years ]

Secondary Outcome Measures:
  • To correlate trough sorafenib level with progression free survival [ Time Frame: 4 years ]
  • To correlate trough sorafenib level with response (disease-control vs progressive disease) by RECIST criteria [ Time Frame: 4 years ]
  • To correlate trough sorafenib level with alpha fetoprotein (AFP) response [ Time Frame: 4 years ]
  • To correlate trough sorafenib level with side effects (rash and hypertension) [ Time Frame: 4 years ]

Estimated Enrollment: 100
Study Start Date: February 2010
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
HCC patients on Sorafenib


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with advanced HCC who are to commence Sorafenib

Inclusion Criteria:

  • ECOG ≤ 2
  • Histologically or cytologically diagnosed hepatocellular carcinoma, or diagnosis on at least one cross-sectional imaging with the characteristic appearance of HCC (i.e. liver lesion with arterial enhancement and portal venous washout)
  • Decision to treat with single agent sorafenib at 400mg bid (dose reductions or interruptions are permitted if side effects occur during treatment)
  • No prior systemic chemotherapy or targeted therapy
  • Child-Pugh liver function class A or B
  • At least one untreated target lesion that can be measured in one dimension according to RECIST
  • Adequate organ functions

Exclusion Criteria:

  • Prior systemic chemotherapy or molecularly targeted therapy
  • Concurrent active malignancy
  • Concomitant strong CYP3A4 induced or inhibitor at a therapeutic dose (see section 6.4.1)
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent
  • Hypertension that cannot be controlled by medications (> 150/100 mmHg despite optimal medical therapy)
  • History of, or known brain metastases (skull metastases allowed), carcinomatous meningitis, or leptomenigeal disease
  • Major surgery (e.g. open abdominal therapy, pelvic, thoracic, orthopaedic or neurosurgery) within 4 weeks of the date of first dose
  • Local-regional treatment (i.e. percutaneous and trans-arterial procedures) within 4 weeks. Restaging CT or MRI scan must be repeated at least 4 weeks after local-regional treatment and within 3 weeks before the date of first dose
  • For patients treated with Yttrium (90Y) radiotherapy, a washout period of 2 months is required.
  • Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol
  • Pregnancy or breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01078311

Contact: Mark Wong, MBBS, FRACP 61298455200 ext 55200

Australia, New South Wales
Westmead Hospital Recruiting
Westmead, New South Wales, Australia, 2145
Sponsors and Collaborators
South West Sydney Local Health District
  More Information

Responsible Party: Mark Wong, Westmead Medical Oncology Identifier: NCT01078311     History of Changes
Other Study ID Numbers: MWWH009
Study First Received: March 1, 2010
Last Updated: March 1, 2010

Keywords provided by South West Sydney Local Health District:
Patients with advanced hepatocellular cancer

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017